NCT06088654 - Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Non Hodgkin Lymphoma

Interventions

DRUG

IPH6501

phase 1 (dose finding) and phase 2 (dose expansion)

Trial Locations (14)

2500

RECRUITING

Wollongong Private Hospital, Wollongong

3168

RECRUITING

Monash Health, Clayton

3910

RECRUITING

Peninsula Private Hospital, Frankston

10029

ACTIVE_NOT_RECRUITING

Icahn School Of Medicine At Mount Sinai, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

13005

NOT_YET_RECRUITING

Hôpital de la Coception, Marseille

63110

RECRUITING

Siteman Cancer Center, St Louis

69002

RECRUITING

Hospices Civils de Lyon, Lyon

90048

RECRUITING

Cedars Sinai, Los Angeles

91010

RECRUITING

City of Hope, Duarte

Unknown

RECRUITING

Austin Health, Heidelberg

RECRUITING

Institute Bergonie, Bordeaux

RECRUITING

Centre Hospitalier Regional Universitaire de Lille, Lille

RECRUITING

Centre Hospitalier Universitaire de Nantes, Nantes